Dual Tracers of 16α-[18F]fluoro-17β-Estradiol and [18F]fluorodeoxyglucose for Prediction of Progression-Free Survival After Fulvestrant Therapy in Patients With HR+/HER2- Metastatic Breast Cancer.

ABSTRACT:

Objective

The purpose of this study was to employ dual tracers 16α-[18F]fluoro-17β-estradiol (¹⁸F-FES) and [18F]fluorodeoxyglucose (¹⁸F-FDG) as imaging biomarkers in predicting progression-free survival (PFS) in ER-positive metastatic breast cancer (MBC) patients receiving fulvestrant therapy.

Methods

We retrospectively analyzed 35 HR+HER2- MBC patients who underwent ¹⁸F-FES and ¹⁸F-FDG PET/CT scans prior to fulvestrant therapy in our center. The SUVmax across all metastatic lesions on the PET/CT were assessed. The heterogeneity of ER expression was assigned by the presence of any ¹⁸F-FES negative lesions for patients with entirely ¹⁸F-FES positive lesions categorized into two groups by the median ratio of FES

SUBMITTER: Liu C 

PROVIDER: S-EPMC7673439 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature